June 17, 2020 / 12:22 PM / 25 days ago

BRIEF-Daré Bioscience Announces Initiation Of Pivotal Phase 3 Study Of DARE-BV1

June 17 (Reuters) - Dare Bioscience Inc:

* DARÉ BIOSCIENCE ANNOUNCES INITIATION OF PIVOTAL PHASE 3 STUDY OF DARE-BV1 IN PATIENTS WITH BACTERIAL VAGINOSIS

* DARE BIOSCIENCE INC - CONTINUE TO ANTICIPATE REPORTING TOPLINE DATA FROM PHASE 3 STUDY OF DARE-BV1 IN 2020

* DARE BIOSCIENCE INC - IF SINGLE PHASE 3 STUDY IS SUCCESSFUL, INTEND TO FILE A NEW DRUG APPLICATION WITH FDA FOR DARE-BV1 IN 2021

* DARE BIOSCIENCE - DARE-BV1 HAS RECEIVED BOTH FAST TRACK, QUALIFIED INFECTIOUS DISEASE PRODUCT DESIGNATIONS FROM FDA FOR TREATMENT OF BACTERIAL VAGINOSIS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below